Please ensure Javascript is enabled for purposes of website accessibility

MYOS CORP Announces Positive Results from Feline Study on Fortetropin

Julia Rivera//June 16, 2021//

Two cats on blanket on brown wall background

MYOS CORP Announces Positive Results from Feline Study on Fortetropin

Julia Rivera //June 16, 2021//

Listen to this article

Press release: MYOS Corp 

MYOS Corp, a research-based advanced nutrition company with divisions that address both Human Nutrition and Animal Health, has announced that researchers from the University of Florida College of Veterinary Medicine presented a poster titled, “Evaluating the Safety and Tolerability of Fortetropin in Cats” at the American College of Veterinary Internal Medicine (ACVIM) Forum which took place June 9-12, 2021. First established in 1983, the ACVIM Forum is a conference that brings information about cutting edge research to thousands of veterinarians from around the world.

Although Fortetropin has been studied extensively in humans and dogs, the nutrition product was never studied in cats up until now. The poster that was presented at the ACVIM Forum highlights that Fortetropin is safe and well tolerated by felines at doses ranging from one gram/day (~200 mg/kg/day) to as high as four gram/day (~800 mg/kg/day) when studied over a two week duration in a placebo-controlled study. This study forms the basis of MYOS’ entry into the feline supplement market with the launch of MYOS Feline Muscle Health Formula.

“I am very excited about the launch of MYOS Feline Health Formula,” said MYOS CEO Joe Mannello. “Since the launch of MYOS Canine Muscle Formula, we have been overwhelmed with a positive response from the marketplace. Dog owners and veterinarians alike have shared with us their stories of incredible animal recoveries from injury or surgery, as well as the overall increase in vitality in elder dogs consuming the product. We felt entering the feline market was the logical next step for MYOS CORP as we continue to aggressively grow our animal health business.” 

“I am optimistic that this product has the potential to be transformative for cats,” said Albert Ahn, D.V.M., chief veterinary adviser, MYOS CORP. “There are very few high-quality nutrition products on the market that address feline sarcopenia and are supported by results from clinical trials. Because Fortetropin is an all-natural nutrition product, we expect it to be well received by feline practitioners, particularly those that belong to the Holistic Veterinary community.”

Manufactured from fertilized chicken egg yolk using a patented, low temperature process, Fortetropin is a proprietary ingredient that has been shown to accelerate gains in muscle mass in multiple human and veterinary clinical studies. In a randomized, double blind, placebo-controlled clinical study conducted at Kansas State University that assessed the impact of Fortetropin on muscle atrophy following TPLO surgery, it was found that dogs that consumed Fortetropin daily did not experience statistically significant decreases in muscle mass following surgery at eight weeks following surgery. In contrast, dogs in the placebo group that were given a macronutrient-matched nutritional supplement did experience statistically significant decreases in mass muscle at this time point. 

A form of age-related muscle loss known as sarcopenia is a major problem for both dogs and cats. Researchers from the University of Pennsylvania reported that geriatric cats (about 15 years of age) have much lower muscle mass scores relative to middle-aged cats (about eight years of age). Sarcopenia impacts the health of cats in multiple ways. For example, chronic kidney disease (CKD) is one of the most common diseases that afflicts cats. Researchers at Tufts University reported that cats that are two kilograms underweight have greater than twice the mortality risk relative to cats with average weight (five kilograms). 

One industry that managed to remain unscathed since the onset of Covid-19 is the U.S. pet food industry. For the past decade, the pet food and treat sector has managed to remain a growth sector. During the first seven months of 2020, it was reported by Nielsen that pet food and treat sales had increased by 4.3 percent relative to the same period in 2019.  During the Covid-19 pandemic, pet adoptions soared with many rescue centers running out of dogs and cats for people to adopt. According to the American Pet Products Association (APPA), 41 percent of cat owners buy premium pet food products. As quoted in The Guardian, Matt Michaelson, founder of cat food company, Smalls, said, “Cat parents want to give their cats the absolute best, but the majority of what’s available is effectively junk food, disguised as health food.” 

MYOS CORP (MYOS), “The Muscle Company,” is a Cedar Knolls, New Jersey based advanced nutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size, lean body mass and reduce muscle atrophy. MYOS believes Fortetropin has the potential to redefine existing standards of physical health and wellness and produces muscle health support products featuring Fortetropin under the names of Yolked, Physician Muscle Health Formula, and MYOS Canine Muscle Formula (Original & Vet Strength).